The raise-ready growth narrative for HealthTech founders

What is a raise-ready growth narrative?

A raise-ready growth narrative is the clear account of who you sell to, why they buy, how you reach them, what proof you have, and what breaks next if capital arrives. It sits in the deck, the data room, the investor FAQ and the founder verbal pitch.

It is not a longer product demo. It is not a vanity metrics slide. It is the commercial logic that makes the round make sense.

Teknon Labs works this problem from the growth side: positioning, channels, funnel and proof packaging. The free raise readiness self-assessment is a quick mirror. Deeper teardowns run through the HealthTech Growth Diagnostic ($1,200; $600 credited toward the first subscription month within 30 days). Ongoing help sits under services. Soft entry point: a free 30-minute call.

What do investors listen for in a HealthTech GTM story?

Four questions, asked in different words across partner meetings:

1. Who is the economic buyer, and who is the clinical champion? If you blur them, diligence gets noisy.
2. Why do you win against the alternatives prospects already name? "Better AI" is not a reason.
3. What is the motion today? Founder-led outbound, partnership, product-led, conference-led, inbound? Pick the real one.
4. What becomes repeatable with this round? Hiring a first AE is not a motion. A defined segment, message, channel and proof pack is.

Related Teknon playbook on site: What investors look for in your traction story. Use it alongside this article; do not treat either as fundraising legal advice.

How should you structure the narrative?

Use seven beats. Keep each beat to a few sentences in the verbal pitch and one slide or less in the deck.

1. Buyer and job

Name the organization type, the champion role, the signer role and the job to be done. Hypothetical: "Community oncology clinics; nurse navigator champions; COO signs; job is reducing manual prior-auth follow-ups after denial."

2. Why now

A concrete trigger: workflow cost, regulation, EHR change, staffing pressure, reimbursement shift. Avoid abstract "AI moment" language unless you can tie it to a buyer budget line.

3. Why you

One wedge. Workflow fit, evidence posture, distribution access, or a data advantage you can explain without mystique. Single wedge beats a list of ten partial advantages.

4. Motion

How the last five conversations started. Be honest. If every deal is a warm intro from your advisor, say so, then say how the round changes that.

5. Proof

What you can show without stretching: design partners, paid pilots, renewal signals, cycle time, qualitative champion quotes you are allowed to use. Separately label clinical evidence vs commercial traction.

6. Economics sketch

How money moves: pilot to contract path, rough sales cycle length band you have observed, who has to approve. Skip fake LTV models if you do not have retention data yet.

7. Use of funds as a GTM plan

Translate the round into segment focus, hires, proof assets and channel bets. "Marketing" as a line item is not a plan.

What counts as traction (and what does not)

Usually counts, when explained:

• Paid pilots with success criteria
• Expansion inside an account
• A repeatable inbound or outbound path you can describe step by step
• Champions who will take a reference call
• Pipeline quality notes: stage definitions that match reality

Usually does not count on its own:

• Waitlist vanity without conversion
• LOIs with no commercial path
• Press mentions with no buyer follow-through
• LinkedIn likes
• "Interest" from logos you cannot reference

Never invent figures, logos or quotes for a deck. Vague and true beats specific and fabricated. Teknon's own public proof language stays limited to verified site points such as a 4.9 Clutch rating, 4.2x average return on engagement, 50+ companies supported and $11M+ revenue influenced. Your deck should follow the same discipline with *your* numbers only.

Evidence checklist before you open the raise

Copy into a tracker:

• [ ] One-sentence buyer + job
• [ ] Two named alternatives prospects mention
• [ ] Current motion written in five steps
• [ ] Last 10 opportunities listed with source and stage
• [ ] Win/loss notes for the last three decisions
• [ ] Pilot success criteria template
• [ ] Security / privacy one-pager ready for diligence
• [ ] Clinical claim list with allowed wording
• [ ] Referenceable champion (or honest "not yet")
• [ ] Hire plan tied to the motion, not to titles alone
• [ ] Deck narrative matches website and LinkedIn

If more than three boxes are empty, fix the growth story before you optimize the animation on slide 11.

How do you rewrite a weak narrative?

Take your current traction slide and run this pass:

1. Delete adjectives. Keep nouns, numbers you can defend, and verbs.
2. Split clinical proof from commercial proof. Mixing them confuses both audiences.
3. Replace "platform" with the job. Investors hear "platform" all day.
4. Add the failure mode. What breaks if the champion leaves? What breaks if IT blocks the feed? Naming risk builds credibility.
5. Align public surfaces. Website hero, LinkedIn About and deck beat 1 should match. Inconsistency reads as early-stage confusion, which is fine only if you acknowledge it and show the next tight loop.

Hypothetical before/after:

• Before: "We are seeing strong interest across the HealthTech landscape with multiple enterprise conversations in flight."
• After: "Eight health-system conversations this quarter; three reached security review; one paid pilot live with a 90-day success metric on documentation time. Motion is founder-led outbound into VP Clinical Operations, with one conference channel producing the first meeting."

The after version invites diligence questions. Soft language does not.

Stage notes (without fake benchmarks)

Pre-seed / seed: Narrative weight sits on problem clarity, design partners and founder motion. Do not cosplay Series A dashboards.

Series A: Investors look harder at repeatability, segment focus and whether a non-founder can run parts of the motion.

Later: Efficiency, expansion motion and channel mix matter more. Still start from buyer and job.

For vertical nuance (MedTech evidence clocks vs SaaS workflow sales), adapt the proof section rather than copying a SaaS template wholesale. Point readers to a dedicated vertical such as life sciences when that story is public.

Where Teknon fits in the raise path

Teknon is a HealthTech growth partner, not a placement agent. Dr. Dereck Mush has advised 40+ HealthTech founders on go to market and fundraising narrative. Useful moments:

• Sharpening positioning before the deck freezes
• Pressure-testing channels and funnel in a Diagnostic
• Building the content and demand system that makes the "use of funds" slide believable (services)
• A short sounding board on the free 30-minute call
• A quick self-check via raise readiness

Bottom line

A raise-ready growth narrative makes your commercial logic inspectable. Name the buyer and the job, tell the truth about the motion, separate proof types, and spend the round on a plan that could actually create repeatability. When you want a teardown or help building the system behind the slides, start with the HealthTech Growth Diagnostic, services, or a free 30-minute call.

FAQ